BRPI1006748A2 - método de tratamento profilático ou terapêutico de fibrose aórtica em um indivíduo, peptídeo intestinal vasoativo (vip), uso do peptídeo intestinal vasoativo (vip), método para reduzir a formação de colágeno ou para realçar a degradação de colágeno na orta de um indivíduo, e, composição para o tratamento profilático ou terapêutico de fibrose aórtica - Google Patents
método de tratamento profilático ou terapêutico de fibrose aórtica em um indivíduo, peptídeo intestinal vasoativo (vip), uso do peptídeo intestinal vasoativo (vip), método para reduzir a formação de colágeno ou para realçar a degradação de colágeno na orta de um indivíduo, e, composição para o tratamento profilático ou terapêutico de fibrose aórticaInfo
- Publication number
- BRPI1006748A2 BRPI1006748A2 BRPI1006748A BRPI1006748A BRPI1006748A2 BR PI1006748 A2 BRPI1006748 A2 BR PI1006748A2 BR PI1006748 A BRPI1006748 A BR PI1006748A BR PI1006748 A BRPI1006748 A BR PI1006748A BR PI1006748 A2 BRPI1006748 A2 BR PI1006748A2
- Authority
- BR
- Brazil
- Prior art keywords
- vip
- prophylactic
- individual
- therapeutic treatment
- vasoactive intestinal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2285—Endothelin, vasoactive intestinal contractor [VIC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2009901425A AU2009901425A0 (en) | 2009-04-02 | Compositions and methods for treatment of aortic fibrosis | |
PCT/AU2010/000391 WO2010111753A1 (en) | 2009-04-02 | 2010-04-06 | Compositions and methods for treatment of aortic fibrosis |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI1006748A2 true BRPI1006748A2 (pt) | 2018-03-06 |
Family
ID=42827427
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI1006748A BRPI1006748A2 (pt) | 2009-04-02 | 2010-04-06 | método de tratamento profilático ou terapêutico de fibrose aórtica em um indivíduo, peptídeo intestinal vasoativo (vip), uso do peptídeo intestinal vasoativo (vip), método para reduzir a formação de colágeno ou para realçar a degradação de colágeno na orta de um indivíduo, e, composição para o tratamento profilático ou terapêutico de fibrose aórtica |
Country Status (19)
Country | Link |
---|---|
US (2) | US8729020B2 (pt) |
EP (1) | EP2413954B1 (pt) |
JP (1) | JP5687266B2 (pt) |
KR (1) | KR101627008B1 (pt) |
CN (1) | CN102711797A (pt) |
AU (1) | AU2010230862B2 (pt) |
BR (1) | BRPI1006748A2 (pt) |
CA (1) | CA2757076C (pt) |
DK (1) | DK2413954T3 (pt) |
ES (1) | ES2462501T3 (pt) |
HK (1) | HK1165271A1 (pt) |
IL (1) | IL215460A (pt) |
MX (1) | MX2011010341A (pt) |
MY (1) | MY180681A (pt) |
NZ (1) | NZ595726A (pt) |
RU (1) | RU2536223C2 (pt) |
SG (1) | SG174966A1 (pt) |
WO (1) | WO2010111753A1 (pt) |
ZA (1) | ZA201107820B (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ597677A (en) | 2005-12-09 | 2013-05-31 | Vectus Biosystems Ltd | Vip fragments and methods of use |
DK2349320T3 (en) * | 2008-10-17 | 2016-09-26 | Vectus Biosystems Ltd | Compositions and methods for the treatment of renal disorders |
EP2990027A1 (en) * | 2014-09-01 | 2016-03-02 | Institut Curie | Skin whitening peptide agents |
CN104980999B (zh) * | 2015-06-19 | 2017-03-08 | 广东欧珀移动通信有限公司 | 一种网络接入方法及移动终端 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101229363A (zh) * | 2000-11-28 | 2008-07-30 | 蒙多生物技术许可股份公司 | 具有血管活性肠肽的生物学活性的用于治疗肺动脉和小动脉高压的化合物 |
JP4824682B2 (ja) * | 2004-06-11 | 2011-11-30 | ベクタス・バイオシステムズ・リミテッド | 循環器病の治療のための組成物および方法 |
NZ597677A (en) * | 2005-12-09 | 2013-05-31 | Vectus Biosystems Ltd | Vip fragments and methods of use |
CA2699241A1 (en) * | 2007-09-11 | 2009-04-02 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
DK2349320T3 (en) * | 2008-10-17 | 2016-09-26 | Vectus Biosystems Ltd | Compositions and methods for the treatment of renal disorders |
-
2010
- 2010-04-06 US US13/262,064 patent/US8729020B2/en active Active
- 2010-04-06 AU AU2010230862A patent/AU2010230862B2/en active Active
- 2010-04-06 CA CA2757076A patent/CA2757076C/en active Active
- 2010-04-06 CN CN2011800017312A patent/CN102711797A/zh active Pending
- 2010-04-06 RU RU2011142268/15A patent/RU2536223C2/ru active
- 2010-04-06 BR BRPI1006748A patent/BRPI1006748A2/pt not_active Application Discontinuation
- 2010-04-06 WO PCT/AU2010/000391 patent/WO2010111753A1/en active Application Filing
- 2010-04-06 DK DK10757953.4T patent/DK2413954T3/da active
- 2010-04-06 MY MYPI2011004649A patent/MY180681A/en unknown
- 2010-04-06 NZ NZ595726A patent/NZ595726A/xx unknown
- 2010-04-06 EP EP10757953.4A patent/EP2413954B1/en active Active
- 2010-04-06 ES ES10757953.4T patent/ES2462501T3/es active Active
- 2010-04-06 JP JP2012502396A patent/JP5687266B2/ja active Active
- 2010-04-06 MX MX2011010341A patent/MX2011010341A/es active IP Right Grant
- 2010-04-06 SG SG2011070778A patent/SG174966A1/en unknown
- 2010-04-06 KR KR1020117025945A patent/KR101627008B1/ko active IP Right Grant
-
2011
- 2011-10-02 IL IL215460A patent/IL215460A/en active IP Right Grant
- 2011-10-25 ZA ZA2011/07820A patent/ZA201107820B/en unknown
-
2012
- 2012-06-14 HK HK12105842.5A patent/HK1165271A1/xx unknown
-
2014
- 2014-04-15 US US14/252,818 patent/US20140235541A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
RU2536223C2 (ru) | 2014-12-20 |
US20140235541A1 (en) | 2014-08-21 |
MY180681A (en) | 2020-12-06 |
NZ595726A (en) | 2013-06-28 |
WO2010111753A1 (en) | 2010-10-07 |
HK1165271A1 (en) | 2012-10-05 |
CN102711797A (zh) | 2012-10-03 |
DK2413954T3 (da) | 2014-05-12 |
CA2757076A1 (en) | 2010-10-07 |
RU2011142268A (ru) | 2013-05-10 |
US20120027850A1 (en) | 2012-02-02 |
ZA201107820B (en) | 2013-09-25 |
AU2010230862B2 (en) | 2014-04-17 |
MX2011010341A (es) | 2012-01-27 |
US8729020B2 (en) | 2014-05-20 |
JP5687266B2 (ja) | 2015-03-18 |
IL215460A0 (en) | 2011-12-29 |
AU2010230862A1 (en) | 2011-11-03 |
CA2757076C (en) | 2017-05-16 |
EP2413954A4 (en) | 2012-11-21 |
IL215460A (en) | 2017-01-31 |
ES2462501T3 (es) | 2014-05-23 |
SG174966A1 (en) | 2011-11-28 |
EP2413954A1 (en) | 2012-02-08 |
KR101627008B1 (ko) | 2016-06-02 |
JP2012522727A (ja) | 2012-09-27 |
KR20120024572A (ko) | 2012-03-14 |
EP2413954B1 (en) | 2014-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO2017003I1 (no) | Kobicistat eller farmasøytisk akseptabelt salt derav og tenofovir alafenamid eller farmasøytisk akseptabelt salt derav, spesielt tenofovir alafenamidfumarat | |
BR112012008854A2 (pt) | combinação, kit de combinação, uso de uma combinação, composição farmacêutica, e, método para tratar câncer em um ser humano | |
ZA200901132B (en) | Human GLP-1 mimetibodies, compositions, methods and uses | |
ZA200709266B (en) | Human GLP-1 mimetibodies, compositions, methods and uses | |
EP2046362A4 (en) | FORMULATION COMPRISING LACTOSERIC PROTEIN AND HYDROLYSATS FOR PROMOTING MUSCLE RECOVERY | |
ZA200800144B (en) | Human placental collagen compositions, processes for their preparation, methods of their use and kits comprising the compositions | |
BRPI0809655A2 (pt) | Método para tratar uma condição em um mamífero, composição farmacêutica, e, kit | |
BRPI0815850A2 (pt) | "método para tratar, retardar a progressão, prevenir ou atrasar o desenvolvimento de esquizofrenia em um individuo, composiçã farmaceuticamente aceitável, kit e método para reforçar uma resposta de um individuo a um antipsicótico" | |
BRPI1006451A2 (pt) | "sistema de tratamento bucal, método para a aplicação de um agente benéfico de tratamento bucal em uma superfície bucal, polipeptídeo e composição de tratamento bucal" | |
TWI350286B (en) | Alkylpiperazine- and alkylhomopiperazine-carboxylate derivatives, their preparation and their application in therapy | |
BRPI0812561A2 (pt) | Formulação liofilizada estável preparada, formulação reconstituída estável, método para preparar formulação reconstituída estável e para tratar indivíduo | |
BR112013019083A2 (pt) | combinação de (a) um imunoconjugado, composição farmacêutica, uso de (a) um imunoconjugado, método de tratamento de uma doença em um individuo, método de estímulo de função celular efetora em um indivíduo e kit destinado ao tratamento de uma doença. | |
IL196965A0 (en) | Preparation of (r,r)-fenoterol and (r,r)-or (r,s)-fenoterol analogues and their use in treating congestive heart failure | |
BRPI0816934A2 (pt) | Estimulador da musculatura facial e bucal | |
BR112012001344A2 (pt) | derivados de 17hidróxi-17-pentafluoroetil-estra-4,9(10)-dieno-11-arila, método de produção destes e uso destes para o tratamento de doenças | |
EP2475358A4 (en) | COMPOSITION WITH ANIONIC CORE FOR THE RELEASE OF THERAPEUTICS AND METHOD FOR THE PRODUCTION AND USE THEREOF | |
IL219318A0 (en) | Pterostilbene (pter) for use in the prevention and/or treatment of skin diseases, damages or injures | |
PT1991292T (pt) | Kit para a regeneração de tecidos adiposos e respectivo método de utilização | |
BRPI0917728A2 (pt) | composição, uso da composição, e, método de prevenção da formação de espuma em uma composição | |
EP2234625B8 (en) | Compositions and methods for treating and preventing skeletal muscle deficiencies | |
EP2427167A4 (en) | METHOD AND COMPOSITION FOR RECOVERING AGED-INFUSED TISSUE LOSS IN THE FACE OR PARTICULAR BODY RANGE | |
BRPI0813423A2 (pt) | Uso de uma composição, e, composição nutricional para a estimulação de uma flora intestinal saudável em pacientes com hiv | |
BRPI1006748A2 (pt) | método de tratamento profilático ou terapêutico de fibrose aórtica em um indivíduo, peptídeo intestinal vasoativo (vip), uso do peptídeo intestinal vasoativo (vip), método para reduzir a formação de colágeno ou para realçar a degradação de colágeno na orta de um indivíduo, e, composição para o tratamento profilático ou terapêutico de fibrose aórtica | |
ZA200903689B (en) | Polymer-ceramic composite and method | |
HK1134286A1 (en) | Aryl-and heteroaryl-ethyl-acylguanidine derivatives, their preparation and their application in therapeutics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |